Medicare Part D reviewed in California

29 July 2007

The US Medicare Part D prescription drug benefit for seniors is the object of a study by the Oakland-based think-tank, the California HealthCare Foundation (CHCF). To date, more than 2.9 million residents of the largest US state in terms of population have enrolled in the federal program and the think-tank notes the availability of "numerous plan choices that vary by premium cost, plan structure and prescription drug coverage."

Although the CHCF finds that the Part D scheme is generally successful, with California having the highest proportion of the qualifying population participating in the drug benefit, the group notes that "many low-income beneficiaries eligible for a subsidy have not enrolled." One area of concern is the wide discrepancy in the proportion of seniors enrolled in different counties of the Pacific coastal state.

For two of the three classes of drug plans available under the Medicare program, the average number of drugs covered has risen and prices fallen.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight